TID

Teledyne e2v HiRel Releases Catalog Radiation Tolerant S-Band (2 GHz to 5 GHz) Ultra-Low Noise Amplifier for Space Applications

Retrieved on: 
수요일, 3월 6, 2024
Other Science, Technology, Research, Other Defense, Contracts, Engineering, Aerospace, Manufacturing, Mobile, Wireless, Defense, Military, Semiconductor, Security, Satellite, Nanotechnology, Other Technology, Telecommunications, Networks, Hardware, Science, Electronic Design Automation, High-electron-mobility transistor, Multimedia, Radar, LNA, TID, Noise, Radio, Radiation, Business development, VDD, DFN, Transistor count, MMIC

View the full release here: https://www.businesswire.com/news/home/20240306331700/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240306331700/en/
    Teledyne e2v HiRel Rad Tolerant S-Band LNA, TDLNA2050SEP (Photo: Business Wire)
    The TDLNA2050SEP LNA leverages monolithic microwave integrated circuit (MMIC) design techniques that deliver exceptional performance in the S-band communication channel.
  • The TDLNA2050SEP amplifier delivers a gain of 17.5 dB from 2 GHz to 5 GHz while maintaining a noise figure of less than 0.4 dB and an output power (P1dB) of 19.5 dBm.
  • “Today, we’re releasing our latest LNA, optimized for space and radar applications,” said Mont Taylor, Vice President and Business Development Manager at Teledyne e2v HiRel.
  • For more information on all of Teledyne e2v HiRel’s space offerings, review our portfolio of semiconductors, converters, processors, and related services here on the Teledyne Defense Electronics website.

VPT Introduces VSC100-2800S Space COTS DC-DC Converters

Retrieved on: 
수요일, 2월 14, 2024
DC-DC, VSC, VPT, NASA, TID, HEI, Private spaceflight, Sale, Radiation, COTS, HEICO, LET, LEO, DLA, Communications satellite

BLACKSBURG, Va., Feb. 14, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE:HEI), announces the addition of the VSC100-2800S to the award-winning VSC Series of space COTS DC-DC converters.

Key Points: 
  • BLACKSBURG, Va., Feb. 14, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE:HEI), announces the addition of the VSC100-2800S to the award-winning VSC Series of space COTS DC-DC converters.
  • Designed for the "NewSpace" market, the VSC Series complements VPT's hermetic hybrid SV / SVL Series of rad hard products available on DLA SMDs.
  • Converters are characterized to LET > 42 MeV/mg/cm2 for catastrophic events and LET > to 30 MeV/mg/cm2 for SET and SEFI.
  • Additional information can be obtained by contacting a local VPT distributor .

VPT Introduces VSC100-2800S Space COTS DC-DC Converters

Retrieved on: 
수요일, 2월 14, 2024
DC-DC, VSC, VPT, NASA, TID, HEI, Private spaceflight, Sale, Radiation, COTS, HEICO, LET, LEO, DLA, Communications satellite

BLACKSBURG, Va., Feb. 14, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE:HEI), announces the addition of the VSC100-2800S to the award-winning VSC Series of space COTS DC-DC converters.

Key Points: 
  • BLACKSBURG, Va., Feb. 14, 2024 /PRNewswire/ -- VPT, Inc., a HEICO company (NYSE:HEI.A) (NYSE:HEI), announces the addition of the VSC100-2800S to the award-winning VSC Series of space COTS DC-DC converters.
  • Designed for the "NewSpace" market, the VSC Series complements VPT's hermetic hybrid SV / SVL Series of rad hard products available on DLA SMDs.
  • Converters are characterized to LET > 42 MeV/mg/cm2 for catastrophic events and LET > to 30 MeV/mg/cm2 for SET and SEFI.
  • Additional information can be obtained by contacting a local VPT distributor .

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Retrieved on: 
월요일, 2월 12, 2024
MRI, International, MD, TID, CRVO, Manuscript, DLB, EEG, Patient, Dementia, Journal, Lewy body, Brain, Pharmaceutical industry

BOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, announced that data from the AscenD-LB Phase 2a trial evaluating treatment with neflamapimod in patients with dementia with Lewy bodies (DLB) were published online in the Journal of Prevention of Alzheimer’s Disease (JPAD). The published manuscript titled “Phase 2a learnings incorporated into RewinD-LB, a Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies,” is available online.

Key Points: 
  • The published manuscript titled “Phase 2a learnings incorporated into RewinD-LB, a Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies,” is available online .
  • “The publication of the EEG and MRI results round out the Phase 2a data that supports the advancement of neflamapimod into late-stage development as a treatment for DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • Our RewinD-LB trial, which we believe is derisked through the incorporation of learnings outlined in the publication, is highly powered and designed to stratify patients most likely to benefit from neflamapimod.
  • As evident in the table, compared to the response in the overall patient population, the magnitude of the neflamapimod treatment effect vs. placebo is substantially higher in the pure DLB patient population.

Teledyne e2v HiRel Releases Single-Supply, Radiation-Tolerant, UHF to S-Band (0.3 GHz to 3 GHz), Ultra-Low Noise Amplifier for Space Applications

Retrieved on: 
화요일, 1월 30, 2024
Technology, Semiconductor, Engineering, Chemicals, Plastics, Aerospace, Nanotechnology, Manufacturing, Government Technology, Hardware, Defense, Multimedia, MMIC, Transistor count, Noise, DFN, Environment, UHF, VDD, Radio, Business development, LNA, Radiation, High-electron-mobility transistor, TID, Cable television

Teledyne e2v HiRel announces the availability of a rad-tolerant UHF to S-band low noise amplifier, model TDLNA0430SEP that is ideal for use in demanding high reliability space applications where low noise figure, minimal power consumption and small package footprint are critical to mission success.

Key Points: 
  • Teledyne e2v HiRel announces the availability of a rad-tolerant UHF to S-band low noise amplifier, model TDLNA0430SEP that is ideal for use in demanding high reliability space applications where low noise figure, minimal power consumption and small package footprint are critical to mission success.
  • This new LNA is developed on a 90nm enhancement-mode pseudomorphic High Electron Mobility Transistor (pHEMT) process.
  • “Today we’re releasing our latest plastic space qualified LNA for harsh environment applications,” said Mont Taylor, Vice President and Business Development Manager at Teledyne e2v HiRel.
  • For more information on all of Teledyne e2v HiRel’s space offerings, review our portfolio of semiconductors, converters, processors, and related services here on the Teledyne Defense Electronics website.

ESS Expands Deployment Footprint in California, Commissions New Project and Advances Energy Center Product Line

Retrieved on: 
수요일, 1월 17, 2024
Technology, Manufacturing, Batteries, Other Energy, Utilities, Other Manufacturing, Green Technology, Alternative Energy, Environment, Energy, Engineering, Nexus, CO2, EW, Forward, USACE, BWP, Forward operating base, Partnership, Kilowatt-hour, Sacramento Municipal Utility District, ESS, ERDC, Corps, Portland General Electric, Water, Energy Centre, TID, SMUD, Renewable energy

This announcement followed deliveries of EW systems to Burbank Water and Power (BWP) and the Turlock Irrigation District (TID), further expanding the company’s deployment footprint in California.

Key Points: 
  • This announcement followed deliveries of EW systems to Burbank Water and Power (BWP) and the Turlock Irrigation District (TID), further expanding the company’s deployment footprint in California.
  • Project Nexus aims to conserve water resources by reducing evaporation while generating clean energy, reducing diesel generation and reducing energy costs.
  • Finally, at the end of 2023, ESS successfully “lifted” its first Energy Center (EC), a key milestone in the manufacturing process.
  • “With these new deployments and progress on our utility-scale Energy Center, ESS is entering 2024 with strong momentum,” said Eric Dresselhuys, ESS CEO.

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Retrieved on: 
화요일, 1월 2, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Diarrhea, DSM-IV codes, Cannabidiol, Lethargy, Partnership, Constipation, Clobazam, Aes, Lamotrigine, Caregiver, Principal, Research, LGS, TID, DEE, ASMS, Medication, Data, Physician, Somnolence, MD, Doctor of Philosophy, DS, SAE, Seizure, Combination, Pharmacokinetics, Appetite, Participation, Patient, Diagnosis, Safety, Levetiracetam, MSCE, Pharmaceutical industry

Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).

Key Points: 
  • Of the 52 participants enrolled in the study, 43 participants were randomized to bexicaserin (DS=4, LGS=24, DEE Other=15) and 9 to placebo (DS=0, LGS=5, DEE Other=4).
  • The median number of countable motor seizures per 28-day period at baseline was 38.8 in the bexicaserin group compared to 20.8 in the placebo group.
  • Most participants (85.7%) in the bexicaserin treated group (n=35) that started the maintenance period tolerated the highest dose (12 mg).
  • 100% of the participants who completed the PACIFIC Study elected to enroll in the ongoing 52-week open-label extension study.

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

Retrieved on: 
월요일, 12월 18, 2023
Hyperphosphatemia, Quality of life, Physician, OLC, TID, Kidney disease, Trial of the century, NDA, MD, Therapy, Pharmacokinetics, Chronic kidney disease, LOS, Patient, Safety, Dialysis, CKD, Pharmaceutical industry

LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC).

Key Points: 
  • LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC).
  • OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
  • “The initiation of patient enrollment in our OLC pivotal clinical trial is a critical milestone as we strive to reduce the pill burden and improve quality of life for individuals with chronic kidney disease on dialysis,” said, Shalabh Gupta, MD, Chief Executive Officer of Unicycive.
  • Once titrated to a clinically effective dose, participants will then be treated for four weeks to evaluate serum phosphate levels.

Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites

Retrieved on: 
월요일, 12월 11, 2023
Science, Food, BID, TID, Disease, Meibomian gland, TARS, Demodex, MGD, Patient, Pharmaceutical industry

Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.

Key Points: 
  • Collarette cure and lid margin erythema cure results were also statistically significant and consistent with the results of previous TP-03 studies.
  • No statistically significant differences were observed between the BID and TID treatment arms and TP-03 was well tolerated.
  • “We are encouraged by these early results, which underscore the potential of TP-03 to address the underlying cause of disease,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus.
  • “We look forward to further analyzing the data from this trial and continued discussions with the U.S. Food and Drug Administration about the best path forward for TP-03 in MGD.”

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Retrieved on: 
수요일, 12월 13, 2023
Research, Neurology, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Medicine, Safety, Pain, Aes, Vertex, Pain management, Patient, TID, Week, Diabetic neuropathy, Medical Affairs Bureau, Autonomic, VRTX, DPN, Șaeș, Neuropathic pain, Vertex Pharmaceuticals, Pharmaceutical industry, Birth control

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 2 dose-ranging study of the selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).
  • The study also included an active reference arm of pregabalin to support the evaluation of the VX-548 treatment effect.
  • VX-548 was generally well tolerated at all doses tested in the study.
  • Most adverse events (AEs) were mild to moderate and there were no serious adverse events (SAEs) related to VX-548.